| Literature DB >> 26970346 |
J K Smith1, L Marciani1,2, D J Humes1,3, S T Francis2, P Gowland2, R C Spiller1,3.
Abstract
BACKGROUND: The relative importance of peripheral nerve injury or central pain processing in painful diverticular disease (DD) is unclear. Functional magnetic resonance imaging (fMRI) has demonstrated that dysfunctional central pain processing predominates in irritable bowel syndrome (IBS). This study aims to identify anticipatory changes in symptomatic DD (SDD) compared to asymptomatic DD (ADD) and IBS patients.Entities:
Keywords: anticipation; diverticular disease; functional MRI; pain
Mesh:
Year: 2016 PMID: 26970346 PMCID: PMC4879512 DOI: 10.1111/nmo.12790
Source DB: PubMed Journal: Neurogastroenterol Motil ISSN: 1350-1925 Impact factor: 3.598
Study Inclusion and Exclusion criteria
| Inclusion criteria | |
| Participants must have either | Symptomatic diverticular disease with short‐lived recurrent abdominal pain on 3 or more days a month and at least one or more colonic diverticulum identified on endoscopy, barium enema, or CT scan |
| Asymptomatic diverticular disease, with no abdominal pain and at least one or more colonic diverticulum identified on endoscopy, barium enema or CT scan | |
| Irritable bowel syndrome, which has been diagnosed by a gastroenterologist at the hospital using ROME II or III criteria | |
| Age | 18–85 years |
| Handedness | Right |
| Informed consent | Yes |
| Exclusion criteria | |
| General: | Pregnant or lactating women |
| Severe co‐morbidity; for example, heart failure, respiratory failure, alcoholism, or drug dependence | |
| Participation in any other study on Nottingham University campus in the last 3 months | |
| No restrictions on the use of HRT, contraceptives medications, or timing of menstrual cycle with the study day were imposed | |
| Metallic implants or objects | Cardiac pacemaker |
| Implanted cardiac defibrillator | |
| Metallic heart valves | |
| Aneurysm clips | |
| Carotid artery vascular clamp | |
| Neurostimulator | |
| Insulin or infusion pump or implanted drug infusion device | |
| Non‐removable cochlear, otologic, or ear implant | |
| Shot or shrapnel inside the body | |
| Metallic fragments in the eye | |
| Medications | Inability to stop NSAIDs (non‐steroidal anti‐inflammatory agents), antibiotics or immunosuppressant drugs or taking antiepileptic, gabapentin, long‐term opiates, or antipsychotic medications |
| Participants taking ondansetron were included in the study, but the medication was not taken until after the study | |
| No exclusions for patients taking antihypertensive medications, diuretics, alcohol, | |
| Inflammatory conditions | Presence of other gastrointestinal conditions such as ulcerative colitis, Crohn's disease and Celiac disease, malignancy, cirrhosis, current hematological malignancy, untreated peptic ulcer disease, Polymyalgia rheumatic |
| Abdominal surgery | Previous abdominal surgery (other than appendectomy, hysterectomy, cholecystectomy and sterilization, hernia repair) |
| Neurological conditions | Previous diagnosis of neurological conditions, for example, stroke, cerebral malignancy, essential tremor, Parkinson's disease and Parkinson plus syndromes, motor neuron disease, dementia, storage disorders, Wilsons disease e.t.c. Peripheral neuropathy (e.g., diabetic, alcohol, stroke) |
| Other | Claustrophobia, broken skin |
Figure 1(A) Study flow diagram and Basic. (B) Paradigm design.
Figure 2Diagram to illustrate participant recruitment. Three participants withdrew from the study: two after the sensory testing and before scanning and one at the break after the first scanning session.
Analysis of group demographics and questionnaire data
| fMRI analysis groups ( | ADD | LSDD | HSDD | IBS |
|---|---|---|---|---|
| Female | 6 (42.9%) | 8 (57.1%) | 11 (78.8%) | 11 (78.8%) |
| Age (years), median (IQR) | 61.5 (60–66.5) | 62 (57.75–66.5) | 54.5*,+ (51–58.75) | 46.5**,+ (41.25–47.75) |
| Previous diverticulitis | 0 | 50% | 35.7% | 0 |
| Past psychiatric history | 28.6% | 7.1% | 21.4% | 42.9% |
| BMI (kg/m2), median (IQR) | 26.5 (23.4–28.1) | 28.0 (25.3–31.6) | 30.5 (24.2–31.4) | 24.4+ (23.5–27.8) |
| Gastrointestinal symptoms | ||||
| Days/month of pain (<24 h), median (IQR) | 0 | 3* (0–11) | 15*** (5–28) | 7.5*** (3.3–12) |
| Pain duration (h), median (IQR) | 0 | 1.5* (0–5) | 6** (3.4–2.4) | 2.5** (0.8–12) |
| Sensory testing | ||||
| Median VAS temperature HAND (°C) (range) | 45.4 (39.5–49) | 43.8 (41.5–47.5) | 43.8 (41–48) | 43.8 (40–49) |
| Median VAS temperature FOOT (°C) (range) | 45.5 (40–48) | 43.5 (42–49.5) | 43.8 (40.5–47.5) | 44.5 (41.5–48.5) |
| Questionnaire data | ||||
| PHQ‐12 SS, median (IQR) | 2.5 (2–3) | 4* (4–5) | 8***,+++ (8–9) | 8*,+ (5–8.75) |
| HAD: anxiety, median (IQR) | 5.5 (3.75–7) | 5.5 (3.25–7) | 8.5*,+ (6.25–11.75) | 7 (3–10) |
| HAD: depression, median (IQR) | 2.5 (1–3) | 2 (1.25–3.75) | 6.5*,+ (4–8.75) | 4.5 (2–5.75) |
| Pain catastrophizing score, median (IQR) | 11 (2.5–14.5) | 3.5 (1.25–15.5) | 14.5+ (10.5–17.75) | 11 (7.75–17.75) |
ADD vs group *p < 0.05, **p < 0.001, ***p < 0.0001. LSDD vs group + p < 0.05, ++ p < 0.001, +++ p < 0.0001. ADD, Asymptomatic diverticular disease; LSDD, Low somatization score diverticular disease; HSDD, High somatization score diverticular disease; IBS, Irritable bowel syndrome; IQR, Interquartile range.
Figure 3Global BOLD effects for anticipation of a painful stimulus applied to the left hand or left foot for the ADD, LSDD, HSDD and IBS groups. Negative BOLD effects are depicted in the blue color spectrum while positive BOLD effects are show in the red–yellow spectrum.
Figure 4Areas which have statistically more significant deactivation in the ADD group than (A) the LSDD group and (B) the HSDD group. (C) shows areas for which positive activations in the LSDD and HSDD groups is statistically more significant than the ADD group. Deactivations are depicted in the blue color spectrum while activations are show in the red–yellow spectrum.
Figure 5Inter‐Group Analysis: Areas which have statistically more significant deactivation or activation during the cue stimulus in the (A) LSDD than the HSDD group, (B) the LSDD than the IBS group, (C) the ADD than the IBS group, and (D) the IBS compared to the HSDD group. Deactivations are depicted in the blue color spectrum while activations are show in the red–yellow spectrum.